Adverse effects of anticancer agents that target the VEGF pathway

[1]  R. Eskander,et al.  Bevacizumab in the treatment of ovarian cancer , 2011, Biologics : targets & therapy.

[2]  R. Markert,et al.  Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs , 2009, Internal medicine journal.

[3]  N. Petrelli,et al.  Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Kong,et al.  Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.

[5]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[6]  D. Sargent,et al.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Shenhong Wu,et al.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.

[8]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.

[9]  C. Robert,et al.  Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  H. Choy,et al.  Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. , 2008, Clinical lung cancer.

[11]  E. Perez,et al.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Lori Minasian,et al.  Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Hanna.  Unlocking the biological clues of lung cancer. , 2008, Journal of Thoracic Oncology.

[14]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[15]  D. Nochy,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[16]  H. Mukai,et al.  Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors , 2008, Cancer science.

[17]  P. Bycott,et al.  Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study , 2008, The Lancet.

[18]  M. Halushka,et al.  Heart failure associated with sunitinib malate , 2008, Cancer.

[19]  T. Choueiri.  Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. , 2008, Current opinion in investigational drugs.

[20]  R. Motzer,et al.  Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma , 2008 .

[21]  M. Haider,et al.  Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium , 2008 .

[22]  R. Figlin,et al.  Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor , 2008 .

[23]  E. Perez,et al.  Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104) , 2008 .

[24]  N. Harbeck,et al.  Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. , 2008 .

[25]  P. Fumoleau,et al.  A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: preliminary results , 2008 .

[26]  G. Linette,et al.  Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Alpers,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[29]  M. Picken,et al.  Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation , 2008, NDT plus.

[30]  Rene Bruno,et al.  Clinical pharmacokinetics of bevacizumab in patients with solid tumors , 2008, Cancer Chemotherapy and Pharmacology.

[31]  Yuki Togashi,et al.  EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[33]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[34]  David Zurakowski,et al.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.

[35]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Howard Mackey,et al.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Daryl Pinedo,et al.  Reversible posterior leukoencephalopathy syndrome associated with oxaliplatin. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Motzer,et al.  Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. , 2007, The Lancet. Oncology.

[39]  K. Flaherty,et al.  Final results of a phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer (mRCC). , 2007 .

[40]  J. Furuse,et al.  Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma , 2007, Cancer science.

[41]  H. Gelderblom,et al.  Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  B. Monk,et al.  Bevacizumab in the treatment of ovarian cancer , 2007, Expert review of anticancer therapy.

[43]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[44]  G. Martín,et al.  Reversible posterior leukoencephalopathy syndrome induced by sunitinib. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Cooney,et al.  Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Drevs,et al.  Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Petr Zatloukal,et al.  Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 , 2007 .

[48]  A. Hauschild,et al.  Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma , 2007 .

[49]  H. Pitot,et al.  Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results , 2007 .

[50]  B. Rovin,et al.  Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma , 2007, Nature Clinical Practice Nephrology.

[51]  H. Izzedine,et al.  Thrombotic microangiopathy and anti-VEGF agents. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  R. Lal,et al.  Interstitial Nephritis Secondary to Bevacizumab Treatment in Metastatic Leiomyosarcoma , 2007, The Annals of pharmacotherapy.

[54]  E. Rock,et al.  Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[55]  D. Nochy,et al.  Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. , 2007, The Lancet. Oncology.

[56]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[57]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[58]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[59]  J. Desai,et al.  Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors , 2006, Annals of Internal Medicine.

[60]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[61]  P. Bergethon,et al.  Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. , 2006, Archives of neurology.

[62]  A. El-Khoueiry,et al.  Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  D. Mutch,et al.  Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma , 2006, Cancer.

[64]  M. Galinier,et al.  Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  H. Gelderblom,et al.  VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  M. Maitland,et al.  Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  M. Socinski,et al.  Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Daohai Yu,et al.  Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  B. Lane,et al.  Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.

[70]  Kevin Camphausen,et al.  Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Betty Y. Y. Tam,et al.  VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. , 2006, American journal of physiology. Heart and circulatory physiology.

[72]  R. Maki,et al.  Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  J. Berlin,et al.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab , 2005, Journal of surgical oncology.

[74]  S. Barry,et al.  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.

[75]  Li-Ling Wu,et al.  Growth-promoting effect of platelet-derived growth factor on rat cardiac myocytes , 2005, Regulatory Peptides.

[76]  T. J. Anderson,et al.  Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed , 2005, Internal medicine journal.

[77]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[79]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[80]  D. Qian,et al.  Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias , 2004, Clinical Cancer Research.

[81]  A. Flyvbjerg,et al.  The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. , 2004, Kidney international.

[82]  C. Oppenheim,et al.  Neuroimaging in Posterior Reversible Encephalopathy Syndrome , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[83]  G. Ciuffetti,et al.  Capillary rarefaction and abnormal cardiovascular reactivity in hypertension , 2003, Journal of hypertension.

[84]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[85]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[86]  J. Haigh,et al.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.

[87]  Napoleone Ferrara,et al.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.

[88]  Brian H Annex,et al.  A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans , 2002, Clinical pharmacology and therapeutics.

[89]  N. Ferrara,et al.  VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism , 2002, Nature.

[90]  Yusu Gu,et al.  A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[91]  M. Detmar,et al.  Thrombospondin‐1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice , 2000, The EMBO journal.

[92]  H. Granger,et al.  VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. , 1998, American journal of physiology. Heart and circulatory physiology.

[93]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[94]  Y. Satow,et al.  Expression of the Vascular Endothelial Growth Factor ( VEGF ) Receptor Gene , KDR , in Hematopoietic Cells and Inhibitory Effect of VEGF on Apoptotic Cell Death Caused by Ionizing Radiation , 2022 .

[95]  G. Arnaldi,et al.  Hypertension‐Induced Changes of Platelet‐Derived Growth Factor Receptor Expression in Rat Aorta and Heart , 1991, Hypertension.

[96]  S. Groshen,et al.  Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  R. Gray,et al.  Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  C. Ozcan,et al.  Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.

[100]  D. Sane,et al.  Angiogenic growth factors and hypertension , 2004, Angiogenesis.